What are biopharma companies hiring CROs for these days? PPD spells it out in bid for $100M IPO
More than eight years after PPD was taken private in a $3.9 billion deal, the 35-years-old contract research organization is bracing for the public market again with a $100 million ask.
Having served all of the top 50 biopharma companies in the world by R&D spending and over 300 biotech fledglings, PPD’s filings highlighted the entrenched role CROs play in an industry chasing an ever dwindling return on investment by pushing for faster timelines and tackling payer resistance to pricey therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.